Loading...
•
Mar 31, 2020
Collegium Q1 2020 Earnings Report
Collegium achieved profitability, driven by Xtampza ER revenue growth and the closing of the Nucynta franchise acquisition.
Key Takeaways
Collegium Pharmaceutical reported GAAP profitability with $0.5 million in net income and non-GAAP net income of $31.2 million in Q1 2020. Xtampza ER prescriptions grew 30% year-over-year. The company updated its 2020 guidance to reflect COVID-19 impact.
Xtampza ER total prescriptions grew 30% year-over-year, reaching 136,736.
Xtampza ER market share of the oxycodone extended-release market increased to 21.8%.
The number of unique prescribers grew to 14,600.
The company closed the acquisition of the U.S. rights to the Nucynta Franchise from Assertio Therapeutics, Inc.
Revenue by Segment
Forward Guidance
Collegium updated its full-year 2020 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...